

# Medical Drug Clinical Criteria

**Subject:** Bizengri (zenocutuzumab-zbco)

**Document #:** CC-0274

**Publish Date:** 04/17/202507/01/2025

**Status:** ~~New~~Revised

**Last Review Date:** 12/09/202405/16/2025

## Table of Contents

[Overview](#)

[Coding](#)

[References](#)

[Clinical Criteria](#)

[Document History](#)

## Overview

This document addresses the use of Bizengri (zenocutuzumab-zbco) injection. Bizengri is a bispecific HER2- and HER3-directed antibody primarily used to treat non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma.

The FDA approved indications for Bizengri include adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (*NRG1*) gene fusion with disease progression on or after prior systemic therapy. Bizengri is also indicated for adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (*NRG1*) gene fusion with disease progression on or after prior systemic therapy. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s)

Bizengri has a black box warning regarding embryo-fetal toxicity. It is recommended to advise patients of this risk and the need for effective contraception.

### Definitions and Measures

**Adenocarcinoma:** Cancer originating in cells that line specific internal organs and that have gland-like (secretory) properties.

**Disease Progression:** Cancer that continues to grow or spread.

**Metastasis:** The spread of cancer from one part of the body to another; a metastatic tumor contains cells that are like those in the original (primary) tumor and have spread.

**Non-small cell lung cancer:** A group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma.

**Unresectable:** Unable to be removed with surgery.

## Clinical Criteria

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

### Bizengri (zenocutuzumab-zbco)

Requests for Bizengri (zenocutuzumab-zbco) may be approved if the following criteria are met:

1. Individual has a diagnosis of advanced, recurrent, unresectable or metastatic non-small cell lung cancer (NSCLC); **AND**

- II. Individual has neuregulin 1 (*NRG1*) gene fusion; **AND**  
III. Individual has disease progression on or after prior systemic therapy;

**OR**

- IV. Individual has a diagnosis of advanced, recurrent, unresectable or metastatic pancreatic adenocarcinoma; **AND**  
V. Individual has neuregulin 1 (*NRG1*) gene fusion; **AND**  
VI. Individual has disease progression on or after prior systemic therapy.

Bizengri (zenocutuzumab-zbco) may not be approved when the above criteria are not met and for all other indications.

**Quantity Limits**

**Quantity Limits**

Drug	Limit
Bizengri ((zenocutuzumab-zbco) 375 mg/18.75 mL	4 vials per 28 days

**Coding**

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

**HCPCS**

<u>C9399</u>	<u>Unclassified drugs or biologicals [Bizengri (zenocutuzumab-zbco)]</u>
<u>J9999</u>	<u>Not otherwise classified, antineoplastic drugs [Bizengri (zenocutuzumab-zbco)]</u>
<u>J9382</u>	<u>Injection, zenocutuzumab-zbco, 1 mg [Bizengri]</u>

**ICD-10 Diagnosis**

All diagnosis pend

<u>C25.0-C25.3</u>	<u>Malignant neoplasm of pancreas, pancreatic duct</u>
<u>C25.7</u>	<u>Malignant neoplasm of other parts of pancreas</u>
<u>C25.8</u>	<u>Malignant neoplasm of overlapping sites of pancreas</u>
<u>C25.9</u>	<u>Malignant neoplasm of pancreas, unspecified</u>
<u>C33</u>	<u>Malignant neoplasm of trachea</u>

**Document History**

Revised: 05/16/2025

**Document History:**

- 05/16/2025 – Annual Review: add recurrent disease to lung and pancreatic cancer criteria. Coding Reviewed: Removed HCPCS NOC C9399, J9999 and all diagnosis pend effective 6/30/25. Added HCPCS J9382 effective 7/1/25. Added ICD-10-CM C25.0-C25.3, C25.7-C25.9, C33, C34.00-C34.92.
- 12/09/2024 – Select Review: Add clinical criteria and quantity limits for Bizengri. Coding reviewed: Added HCPCS NOC C9399, J9999, and all diagnosis pend for Bizengri.

**References**

Formatted Table

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Updated periodically.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.
4. NCCN Clinical Practice Guidelines in Oncology™. © 2025 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on March 14, 2025.
  - a. Non-Small Cell Lung Cancer. V3.2025. Revised January 14, 2025.
  - b. Pancreatic Adenocarcinoma. V2.2025. Revised February 3, 2025.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association